宋美玲

微小残留病（MRD）是指经过治疗后仍然存活的肿瘤细胞群体。在临床上，MRD检测对于疾病复发的预测结果和进一步治疗策略的强度选择至关重要。尽管目前MRD检测的方法有很多种，包括流式细胞术（FCM）、聚合酶链式反应（PCR）、高通量测序（NGS）分析等，这些方法都有其局限性。本综述全面概述了MRD检测技术的优点及其面临的挑战，引入了新兴的MRD检测技术，进而探讨了MRD检测的临床应用，期望为未来研究提供新思路，推动医学和生物科学领域的发展。

微小残留病；MRD检测技术；临床应用

[1] Szczepański T,Willemse MJ,Kamps WA,van Wering ER,Langerak AW,van Dongen JJ.Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia:proposal for an easy strategy.Med Pediatr Oncol.2001;36(3):352-358. [2] Rosenberg AS,Brunson A,Paulus JK,et al.Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.Blood Cancer J.2017;7(9):e605.Published 2017 Sep 8. [3] Borowitz MJ,Wood BL,Devidas M,et al.Prognostic significance of minimal residual disease in high-risk B-ALL:a report from Children's Oncology Group study AALL0232.Blood.2015;126(8):964-971. [4] 王卫国.急性白血病微小残留病检测方法临床应用的研究进展[J].山东医药,2017,57(38):110-113. [5] Tiso F,Koorenhof-Scheele TN,Huys E,et al.Genetic diversity within leuke-mia-associated immunophenotype-defined subclones in AML.Ann Hematol.2022;101(3):571-579. [6] He Z,Chen Z,Tan M,et al.A review on methods for diagnosis of breast cancer cells and tissues.Cell Prolif.2020;53(7):e12822. [7] Wang X,Liu Y,Liu H,et al.Recent advances and application of whole genome amplification in molecular diagnosis and medicine. MedComm(2020).2022;3(1):e116.Published 2022 Feb 3. [8] van Dongen JJ,Seriu T,Panzer-Grümayer ER,et al.Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.Lancet.1998;352(9142):1731-1738. [9] Schumich A,Maurer-Granofszky M,Attarbaschi A,et al.Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.Pediatr Blood Cancer.2019;66(5):e27590. [10] Behjati S,Tarpey PS.What is next generation sequencing?.Arch Dis Child Educ Pract Ed.2013;98(6):236-238. [11] Sims D,Sudbery I,Ilott NE,Heger A,Ponting CP.Sequencing depth and coverage:key considerations in genomic analyses.Nat Rev Genet.2014;15(2):121-132. [12] Schumich A,Maurer-Granofszky M,Attarbaschi A,et al.Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.Pediatr Blood Cancer.2019;66(5):e27590. [13] Setiadi A,Owen D,Tsang A,Milner R,Vercauteren S.The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.Int J Lab Hematol.2016;38(5):527-534. [14] Della Starza I,De Novi LA,Santoro A,et al.Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.Leuk Lymphoma.2019;60(11):2838-2840. [15] Taylor SC,Laperriere G,Germain H.Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets:from variable nonsense to publication quality data.Sci Rep.2017;7(1):2409.Published 2017 May 25. [16] Zhu G,Ye X,Dong Z,et al.Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.J Mol Diagn.2015;17(3):265-272. [17] Villegas-Ruíz V,Olmos-Valdez K,Castro-López KA,et al.Identification and Validation of Novel Reference Genes in Acute Lymphoblastic Leukemia for Droplet Digital PCR.Genes(Basel).2019;10(5):376.Published 2019 May 17. [18] Minervini A,Francesco Minervini C,Anelli L,et al.Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia.Oncotarget.2016;7(52):86469-86479. [19] Nagayama S,Low SK,Kiyotani K,Nakamura Y.Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy.Cancers(Basel).2021;13(19):4803.Published 2021 Sep 25. [20] Stergiopoulou D,Markou A,Strati A,et al.Comprehensive liquid biopsy analysis as a tool for the early detection of minimal residual disease in breast cancer.Sci Rep.2023;13(1):1258.Published 2023 Jan 23. [21] Sardarabadi P,Kojabad AA,Jafari D,Liu CH.Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer(NSCLC).Biosensors(Basel).2021;11(10):394.Published 2021 Oct 15. [22] Stow P,Key L,Chen X,et al.Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.Blood.2010;115(23):4657-4663. [23] Pui CH,Pei D,Coustan-Smith E,et al.Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia:a prospective study.Lancet Oncol.2015;16(4):465-474. [24] 李晓帆,王少元.多发性骨髓瘤微小残留病检测及其临床应用[J].诊断学理论与实践,2017,16(05):472-476. [25] Ladetto M,Böttcher S,Kröger N,Pulsipher MA,Bader P.Methods and role of minimal residual disease after stem cell transplantation. Bone Marrow Transplant.2019;54(5):681-690.

点击下载PDF